Plethora Solutions

Licensing Opportunity

Fortacin™ was filed with the European Medicines Agency (EMA) in May 2012, and obtained a marketing authorization from the European Commission on 19 November 2013.

Global licensing and distribution opportunities for Fortacin™ are now available. For further information please contact:

Mike Wyllie
CSO, Plethora Solutions
T: +44 20 3077 5400

This Product is a proprietary development stage pharmaceutical although the European MAA has been authorized by the European Commission. Information contained on this website is provided for business development and investor relations purposes only. Patients who suffer or believe they suffer from PE should contact their physician in the first instance.